HiFiBiO Therapeutics is an emerging multinational biotherapeutics company mobilizing the human immune system to combat disease. We integrate deep-rooted biological expertise with our comprehensive single-cell profiling technologies to rapidly discover and advance a pipeline of antibody drugs to treat cancer and autoimmune disorders.
More About HiFiBiO
HFB30132A study design is published in ClinicalTrial.gov and primary data readout is expected in late 2020 CAMBRIDGE, Mass. – October 26, 2020 – HiFiBiO Therapeutics, a multinational biotherapeutics company with unique expertise in immune modulation and single-cell science, today announced the successful completion of the first cohort of the Phase I study (NCT04590430) of HFB30132A, … Continued
The Commonwealth Institute Recognizes Women Leaders in Massachusetts Demonstrating Impact, Inspiration, and Innovation across Healthcare Industry CAMBRIDGE, Mass., – September 24, 2020 – HiFiBiO Therapeutics today announced its CEO, Liang Schweizer, PhD, has been recognized with an Extraordinary Women Advancing Healthcare Award (EWAH) by The Commonwealth Institute (TCI), the leading nonprofit organization devoted to advancing … Continued
CAMBRIDGE, Mass., – September 17, 2020 – HiFiBiO Therapeutics is presenting a novel approach for patient stratification demonstrating its proprietary Drug Intelligent Science (DIS™) single-cell platform at the American Association for Cancer Research (AACR) Tumor Heterogeneity Virtual Special Conference taking place today. The company is a pioneer of novel antibody drug discovery and development, leveraging … Continued
HFB30132A study design is published in ClinicalTrial.gov and primary data readout is expected in late 2020 CAMBRIDGE, Mass. – October 26, 2020 – HiFiBiO Therapeutics, a multinational biotherapeutics company with unique expertise in immune modulation and single-cell science, today announced the successful completion of the first cohort of the Phase I study (NCT04590430) of HFB30132A, … Continued
Drug Discovery and Development Expertise
Our scientific leadership team brings decades of drug R&D experiences at leading pharmaceutical companies, along with a proven track record of delivering multiple marketed immuno-oncology and oncology drugs, as well as clinical candidates. We understand what it takes to advance a full pipeline of novel antibody drugs to treat cancer, autoimmune disorders and other unmet medical needs around the world.
Transformational Single-Cell Platform
As a pioneer in ultra-high-throughput phenotyping and genotyping single-cell analysis, we are enabling a paradigm shift in biotherapeutic discovery and development efforts. Our proprietary antibody screening CelliGO™ system combines with our Drug Intelligent Science (DIS™) to enable rapid identification of differentiated therapeutic molecules and significantly enhance clinical probability of success.
Unique Immune Profiling Translational Focus
Building upon our internal proprietary translational capabilities for single cell immune profiling, we have engaged the world’s top clinical immunologists and oncologists to drive a clinical development strategy that better connects biological targets to patient characteristics. Our primary indication drivers are unmet medical needs and deep understanding of mechanisms of action.
Open-Innovation Strategy
We continue to establish strategic partnerships with leading pharmaceutical and biotechnology companies, as well as academic institutions to accelerate the development of novel R&D technology platforms and identification of innovative therapeutics to improve patient care. All of our collaborations are architected for speed and driven by our scientific strategy.
Dynamic and Sustainable Pipeline
We are developing a robust pipeline of novel therapeutic antibodies to modulate multiple immune cell types, initially focused on regulatory T cells and Myeloid-derived suppressor cells, to combat cancer and autoimmune disorders. Currently, we are advancing 10 internal R&D programs, majority first-in-class, toward the clinic with multiple preclinical candidates demonstrating proof of concept in animal models.
Our scientific leadership team brings decades of drug R&D experiences at leading pharmaceutical companies, along with a proven track record of delivering multiple marketed immuno-oncology and oncology drugs, as well as clinical candidates. We understand what it takes to advance a full pipeline of novel antibody drugs to treat cancer, autoimmune disorders and other unmet medical needs around the world.
As a pioneer in ultra-high-throughput phenotyping and genotyping single-cell analysis, we are enabling a paradigm shift in biotherapeutic discovery and development efforts. Our proprietary antibody screening CelliGO™ system combines with our Drug Intelligent Science (DIS™) to enable rapid identification of differentiated therapeutic molecules and significantly enhance clinical probability of success.
Building upon our internal proprietary translational capabilities for single cell immune profiling, we have engaged the world’s top clinical immunologists and oncologists to drive a clinical development strategy that better connects biological targets to patient characteristics. Our primary indication drivers are unmet medical needs and deep understanding of mechanisms of action.
We continue to establish strategic partnerships with leading pharmaceutical and biotechnology companies, as well as academic institutions to accelerate the development of novel R&D technology platforms and identification of innovative therapeutics to improve patient care. All of our collaborations are architected for speed and driven by our scientific strategy.
We are developing a robust pipeline of novel therapeutic antibodies to modulate multiple immune cell types, initially focused on regulatory T cells and Myeloid-derived suppressor cells, to combat cancer and autoimmune disorders. Currently, we are advancing 10 internal R&D programs, majority first-in-class, toward the clinic with multiple preclinical candidates demonstrating proof of concept in animal models.
